Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab plus lenalidomide and dexamethasone with or without bortezomib in newly diagnosed transplant-ineligible non-frail elderly multiple myeloma
2020-004602-59Phase 3Active
- Sponsor
- CHU de Poitiers
- Start
- Sep 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of isatuximab, lenalidomide, dexamethasone and bortezomib in multiple myeloma (MM) (2 arms), sponsored by CHU de Poitiers. Primary endpoint: MRD 10^-5 incidence rate at 18 months. Started Sep 2020; status: active.
02
Drugs
isatuximablenalidomidedexamethasonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2020-004602-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004602-59.